China’s NMPA granted clinical trial clearance for CSPC Pharmaceutical’s JMT-206 for weight management in obese or overweight patients with at least one comorbidity. The clearance allows CSPC to move JMT-206 into human studies in China and advance a program focused on obesity as a chronic disease indication. JMT-206’s entry into clinical testing follows global momentum toward pharmacologic obesity management and places CSPC among domestic developers seeking locally conducted trials and regulatory validation. The company will now initiate clinical operations and patient recruitment under NMPA oversight.